表紙
市場調查報告書

醫療用新興生物材料

Novel Biomaterials for Medical Applications

出版商 Frost & Sullivan 商品編碼 553370
出版日期 內容資訊 英文 45 Pages
商品交期: 最快1-2個工作天內
價格
醫療用新興生物材料 Novel Biomaterials for Medical Applications
出版日期: 2017年07月27日內容資訊: 英文 45 Pages
簡介

本報告提供全球醫療用生物材料技術及其新興產業相關策略展望,並統整了主要技術開發動態及產業展望的分析,參與既有和新興市場的企業角色與策略回顧,以及專利動態等。

第1章 執行摘要

第2章 技術區分和分析

  • 生物材料的4個主要級別佔據了90%以上的全球醫療用生物材料市場
  • 生物材料的臨床用規模在心血管用途極大,次之是整形外科
  • 重視醫療用置入物的功能面及耐用性,全球技術開發領航者
  • 高分子生物材料用途的商業魅力及IP的高集中度
  • 橫跨各種醫療用途的生物材料,其相應的經濟性、技術性影響促進全球R&D活動
  • 聚乙烯、 鈦,矽橡膠等生物材料最常被用來製造臨床上有效的醫療置入物,應用也最廣泛
  • 生物材料新興級別的需求擴大,推動亞太地區的產品開發活動
  • 金屬及金屬合金的3D列印,使製造出與海綿骨功能類似的置入物成為可能

第3章 全球技術開發動向

  • 顯示生物材料安全性、有效性的臨床實驗促進帶入整理價值鏈
  • 金屬與高分子組合的混合生物材料提升了醫療用置入物的臨床價值
  • 凸顯置入物的臨床價值,對於持續引進新型級別的生物材料相當重要
  • 金屬高分子生物材料具備受到風險投資及私募股權公司投資的高可能性
  • 民間投資有80%以上受到生物材料技術開發及臨床頻價的限制

第4章 給產業利害相關者的主要建議

  • 可取得執照的技術是高分子 & 天然生物材料的臨床用途非常廣泛
  • 技術開發者多元化處理重點是強化醫療置入物的有效性、耐用性
  • 即便研究補助金的可使用性很低,公司內聚合物生物材料的研究規模依然很大

第5章 專利情況評估

  • 被授權、應用的專利比率在用於醫療用途的各級別生物材料中取得適當平衡
  • 西班牙和德國是擁有重要專利的管轄區域,聚焦於用於組織再生的生物材料合成
  • 原油水凝膠生物材料在製造藥物傳遞系統極為有效,受到積極研究
  • 主要契約

第6章 關於FROST AND SULLIVAN

目錄
Product Code: D7D9

Investing in Creating and Acquiring Innovative IP Is Vital to Current Competitive Landscape

This Research Service (RS) offers a strategic perspective on the global emerging industry of biomaterial technologies for various medical applications. This research service is segmented into three chapters, with the first two focusing on analysis of the top trends from both technology and industry perspectives. The third chapter brings out the synergies for partnership initiative within the industry, reviewing the roles and strategies of both existing and emerging participants.

Key Questions Answered by this RS:

  • 1. What is the role played by NPD (new product development) and R&D (research and development) initiatives in improving the overall adoption of biomaterials technologies across medical applications?
  • 2. What are the ongoing shifts in the healthcare needs which are largely driving research and development of biomaterials?
  • 3. What are the potential technology-enabled business opportunities that could be explored by existing competitors, and new players entering into the global industry for the biomaterials?
  • 4. Investments in hybrid biomaterials are expected to increase. What are the strategic priorities of existing and new participants in developing the global market?

Table of Contents

1.0. EXECUTIVE SUMMARY

  • 1.1. Scope of Research
  • 1.2. Research Methodology
  • 1.3. High Scope for Funding Research on Applications of PMMA, PEEK, and PLA
  • 1.4. Application of Biomaterials for Tissue Regeneration is an Actively Explored Area of Research Worldwide
  • 1.5. Success of Clinical Trials is Critical to Market Expansion Efforts of Leading Medical Technology Developers

2.0. TECHNOLOGY SEGMENTATION AND ANALYSIS

  • 2.1. Four Major Class of Biomaterials Constitute Over 90% of the Global Market for Medical Applications of Biomaterials
  • 2.2. The Magnitude of Clinical Applications of Biomaterials is Very High for Cardiovascular Applications, Followed by Orthopedic
  • 2.3. Global Technology Development Initiatives Focus on Enhancing Functional Aspects and Durability of Medical Implants
  • 2.4. Commercial Attractiveness and Intensity of IP for Applications of Polymeric Biomaterials is High
  • 2.5. Favorable Economical and Technical Impact of Biomaterials across Various Medical Applications Drive Global R&D Efforts
  • 2.6. Polyethylene, Titanium Alloys, Silicone Rubber are Most Widely Used Biomaterials in Fabrication of Clinically Effective Medical implants
  • 2.7. Growing Demand for Newer Classes of Biomaterials Push Product Development Efforts across the Asia Pacific Region
  • 2.8. 3D Printing of Metals and Metal Alloys Enable Fabrication of Implants that Mimic Functions of Cancellous Bone Structures

3.0. GLOBAL TECHNOLOGY DEVELOPMENT TRENDS

  • 3.1. Clinical Trials Demonstrating Safety and Efficacy of Biomaterials Drive their Adoption across the Value Chain
  • 3.2. Hybrid Biomaterials that Combine Metals and Polymers Increase the Clinical Value of Medical Implants
  • 3.3. Demonstrating Clinical Value of Implants is Critical to Sustainable Adoption of Newer Classes of Biomaterials
  • 3.4. Metallic and Polymeric Biomaterials Exhibit High Potential for Investments from Venture Capital and Private Equity Firms
  • 3.5. Over 80% of Private Investments is Restricted to Technology Development and Clinical Evaluation of Biomaterials

4.0. KEY RECOMMENDATIONS TO INDUSTRY STAKEHOLDERS

  • 4.1. Technologies Available for Licensing are Very High for the Clinical Application of Polymeric & Natural Biomaterials
  • 4.2. Diversification Efforts of Technology Developers Focus on Enhancing Effectiveness and Durability of Medical Implants
  • 4.3. Magnitude of In-house Scientific Research is Very High for Polymeric Biomaterials Despite Low Availability of Research Grants

5.0. PATENT LANDSCAPE ASSESSMENT

  • 5.1. The Ratio of Granted and Applied Patents Strike a Right Balance across Various Classes of Biomaterials Used in Medical Applications
  • 5.2. Spain and Germany are Jurisdictions with Key Patents Focusing on the Synthesis of Biomaterials for Tissue Regeneration Applications
  • 5.3. Cured-oil Hydrogel Biomaterials are Actively Explored as Effective Carriers in the Fabrication of Drug Delivery Systems
  • 5.4. 3D Printing Techniques and Materials are Actively Explored by Academic Research Groups for Fabricating Medical Implants
  • 5.5. Key Contacts
  • 5.5. Key Contacts (continued)
  • Legal Disclaimer

6.0. THE FROST & SULLIVAN STORY

  • 6.1. The Frost & Sullivan Story
  • 6.2. Value Proposition: Future of Your Company & Career
  • 6.3. Global Perspective
  • 6.4. Industry Convergence
  • 6.5. 360° Research Perspective
  • 6.6. Implementation Excellence
  • 6.7. Our Blue Ocean Strategy